<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02211742</url>
  </required_header>
  <id_info>
    <org_study_id>CUI_001</org_study_id>
    <nct_id>NCT02211742</nct_id>
  </id_info>
  <brief_title>Dapagliflozin in Type 1 Diabetes</brief_title>
  <acronym>DapaT1DM</acronym>
  <official_title>Short-term Effects of Dapagliflozin on Fasting and Postprandial Glucose Homeostasis in Male Type 1 Diabetes Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University Innsbruck</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Bern</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University Innsbruck</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dapagliflozin is a highly selective, reversible and potent inhibitor of the
      sodium-glucose-linked Transporter 2 (SGLT2), which was successfully investigated for its use
      as a treatment option in type 2 diabetes mellitus. The effect of dapagliflozin is an
      increased glucosuria, and it was shown that mean blood glucose concentrations and
      postprandial glucose excursion in special were significantly reduced in type 2 diabetic
      patients. Due to its mechanism-of action it seems likely that also type 1 diabetic patients
      will benefit from dapagliflozin. The present study is focused on the effects of dapagliflozin
      on fasting glucose homeostasis and postprandial glucose excursion in male type 1diabetic
      patients. Participants will subsequently receive 10 milligrams of dapagliflozin and placebo
      for 3 days (equals 2 x 30mg per cross-over period) in a double-blind, randomised, cross-over
      design. The effects will be measured via euglycemic hyperinsulinemic clamp studies (fasting
      glucose homeostasis) and euglycemic oral glucose tolerance clamp tests (postprandial glucose
      excursions).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>fasting glucose homeostasis</measure>
    <time_frame>study visit, immediatly</time_frame>
    <description>During hyperinsulinemic, euglycemic clamp studies, fasting glucose homeostasis will be determined for both, dapagliflozin and placebo.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>postprandial glucose homeostasis</measure>
    <time_frame>study visit, immediatly</time_frame>
    <description>During euglycemic oral glucose tolerance clamp tests, postprandial glucose excursion will be determined and compared between dapagliflozin and placebo.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Fasting Glucose</condition>
  <condition>Glucose Excursion</condition>
  <condition>Glycemic Control</condition>
  <arm_group>
    <arm_group_label>dapagliflozin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10mg dapagliflozin per 24h for 3 days per cross-over phase (equals 2 x 30mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo sugar pills</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo tablet, 1 per 24h for 3 days in total per cross-over phase (equals 2 x 3 tablets)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>euglycemic hyperinsulinemic clamp tests and euglycemic oral glucose tolerance clamp tests after the short-term (i.e.: 3 days, equals 10mg / 24h) intake of dapagliflozin</description>
    <arm_group_label>dapagliflozin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 diabetes mellitus (duration of disease at least 5 years)

          -  C-peptide concentration &lt; 0.2Âµg/l

          -  male sex

          -  aged 18 to 60 years

          -  Body Mass Index 20 - 25 kg/m2

          -  no measurable, clinically relevant ketonuria

        Exclusion Criteria:

          -  insufficient venous status on both forearms

          -  renal and/or hepatic insufficiency (including microalbuminuria and/or
             albumin/creatinin-ratio)

          -  history of cancer

          -  intake of medication and/or substances capable to influence insulin sensitivity within
             the last 3 months prior to study inclusion

          -  alcohol- and/or drug abuse, nicotine consumption &gt; 5 cigarettes / 24h

          -  brittle-diabetes

          -  history of severe hypoglycemia, defined as the need for foreign assistance independent
             of actual blood glucose concentration measured

          -  history or evidence of any other clinically significant disorder, condition or disease
             other than those outlined above that, in the opinion of the investigator may
             compromise the ability of the participant to give written informed consent, would pose
             a risk to subject safety, or interfere with the study evaluation, procedures or
             completion.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus Laimer, PD MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University Innsbruck, Department of Internal Medicine I</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Markus Laimer, PD MD</last_name>
    <phone>0043(0)512504</phone>
    <phone_ext>81411</phone_ext>
    <email>Markus.Laimer@uki.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christoph Ebenbichler, Prof MD</last_name>
    <phone>0043(0)512504</phone>
    <phone_ext>81394</phone_ext>
    <email>Christoph.Ebenbichler@i-med.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University Innsbruck, Department of Internal Medicine I</name>
      <address>
        <city>Innsbruck</city>
        <state>Tirol</state>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Laimer, PD MD</last_name>
      <phone>0043(0)512504</phone>
      <phone_ext>81411</phone_ext>
      <email>Markus.Laimer@uki.at</email>
    </contact>
    <contact_backup>
      <last_name>Christoph Ebenbichler, Prof MD</last_name>
      <phone>0043(0)512504</phone>
      <phone_ext>81394</phone_ext>
      <email>Christoh.Ebenbichler@i-med.ac.at</email>
    </contact_backup>
    <investigator>
      <last_name>Markus Laimer, PD MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christoph Ebenbichler, Prof MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andreas Melmer, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pavle Adamovski, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <reference>
    <citation>DeFronzo RA, Hompesch M, Kasichayanula S, Liu X, Hong Y, Pfister M, Morrow LA, Leslie BR, Boulton DW, Ching A, LaCreta FP, Griffen SC. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care. 2013 Oct;36(10):3169-76. doi: 10.2337/dc13-0387. Epub 2013 Jun 4.</citation>
    <PMID>23735727</PMID>
  </reference>
  <reference>
    <citation>Abdul-Ghani MA, DeFronzo RA. Dapagliflozin for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2013 Aug;14(12):1695-703. doi: 10.1517/14656566.2013.812632. Epub 2013 Jun 26. Review.</citation>
    <PMID>23800130</PMID>
  </reference>
  <reference>
    <citation>Mather A, Pollock C. Glucose handling by the kidney. Kidney Int Suppl. 2011 Mar;(120):S1-6. doi: 10.1038/ki.2010.509. Review.</citation>
    <PMID>21358696</PMID>
  </reference>
  <reference>
    <citation>Plosker GL. Dapagliflozin: a review of its use in type 2 diabetes mellitus. Drugs. 2012 Dec 3;72(17):2289-312. doi: 10.2165/11209910-000000000-00000. Review.</citation>
    <PMID>23170914</PMID>
  </reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2014</study_first_submitted>
  <study_first_submitted_qc>August 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2014</study_first_posted>
  <last_update_submitted>April 7, 2015</last_update_submitted>
  <last_update_submitted_qc>April 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University Innsbruck</investigator_affiliation>
    <investigator_full_name>Markus Laimer</investigator_full_name>
    <investigator_title>PD MD</investigator_title>
  </responsible_party>
  <keyword>dapagliflozin</keyword>
  <keyword>fasting glucose</keyword>
  <keyword>postprandial glucose excursion</keyword>
  <keyword>euglycemic hyperinsulinemic clamp</keyword>
  <keyword>euglycemic oral glucose tolerance test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

